Takeda Canada Re-acquires Commercial Rights To ACTOS

Takeda Canada has re-acquired the Canadian commercial rights to ACTOS, an oral treatment for type 2 diabetes, from Eli Lilly Canada. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999.

The company said that ACTOS was approved by Health Canada as monotherapy to decrease insulin resistance and blood glucose levels in patients with type 2 diabetes mellitus, in September 2000.

Reportedly, Takeda has taken over responsibility for ACTOS in the Canadian market effective mid-June. The company already sells ACTOS in many other territories, including the US, Japan and most of Europe.

Daaron Dohler, general manager at Takeda Canada, said: Reacquiring the commercial rights to ACTOS is Takeda’s first opportunity to establish a commercial presence in Canada. It also underscores Takeda’s ongoing efforts to reinforce our global operations and build a stronger presence in North

America.